SAN DIEGO, March 27, 2026
ARS Pharmaceuticals has received U.S. FDA approval to update the labeling of neffy® (epinephrine nasal spray), removing the previous age restriction and allowing broader access for patients weighing 33 lbs. or more. This regulatory milestone significantly expands the use of a needle-free emergency treatment for anaphylaxis, particularly benefiting younger pediatric populations who previously faced eligibility limitations.
Expanded Access to Needle-Free Anaphylaxis Treatment
The updated labeling eliminates the requirement for pediatric patients to be at least four years old, focusing solely on weight-based eligibility (≥33 lbs.). This change is a critical advancement in emergency allergy care, as anaphylaxis remains a life-threatening condition that requires immediate intervention. The nasal spray format offers a non-invasive alternative to traditional epinephrine auto-injectors, addressing common barriers such as needle anxiety, administration complexity, and delayed treatment.
Clinical considerations highlight that a significant portion of pediatric patients needing epinephrine fall below the previous age threshold. By removing this limitation, caregivers can now act faster and more confidently during emergencies, improving the likelihood of timely treatment and reducing complications associated with delayed dosing.
Regulatory and Clinical Advancements in Allergy Management
Advertisement
The FDA’s decision reflects growing support for innovative drug delivery systems that improve patient compliance and accessibility. The updated label also introduces enhanced usage flexibility, including guidance on dosing behavior, storage conditions, and temperature stability. Notably, neffy can be used even after exposure to temperature fluctuations or accidental freezing, provided it is properly thawed.
These updates demonstrate regulatory confidence in the product’s safety, stability, and real-world usability, reinforcing its role as a reliable frontline treatment for severe allergic reactions. The move aligns with broader regulatory priorities to expand access to essential medicines while maintaining stringent quality and efficacy standards.
Market Impact and Innovation in Drug Delivery
From a business perspective, this approval strengthens ARS Pharmaceuticals’ position in the emergency allergy treatment market, which continues to face challenges related to underutilization of epinephrine therapies. Despite millions of individuals at risk, a relatively small percentage consistently carry or use prescribed auto-injectors.
The introduction of a portable, easy-to-use, needle-free alternative has the potential to improve adoption rates and expand market reach. Additionally, planned enhancements such as including carrying cases with prescriptions further support patient convenience and product accessibility. This development underscores a broader industry trend toward patient-centric innovation and differentiated drug delivery technologies.
Patient-Centric Benefits and Real-World Impact
For patients and caregivers, the updated labeling represents a meaningful shift toward greater accessibility, ease of use, and confidence in emergency situations. Anaphylaxis can occur suddenly and escalate within minutes, making rapid administration of epinephrine critical for survival.
The nasal spray format simplifies administration, particularly for children, and reduces the hesitation often associated with injectable devices. By addressing these barriers, neffy has the potential to increase timely intervention rates, reduce emergency complications, and ultimately save lives. The nasal spray format simplifies administration, particularly for children, and reduces the hesitation often associated with injectable devices. By addressing these barriers, neffy has the potential to increase timely intervention rates, reduce emergency complications, and ultimately save lives.
Policy and Public Health Significance
This regulatory update highlights the importance of policy decisions that prioritize accessibility and usability in life-saving treatments. With millions of individuals affected by severe allergic reactions, expanding access to user-friendly therapies aligns with public health goals of reducing preventable morbidity and mortality.
The FDA’s approval also signals continued encouragement of innovation in drug-device combinations, particularly those that enhance real-world effectiveness. As healthcare systems increasingly emphasize patient adherence and early intervention, such advancements are likely to shape future regulatory and policy frameworks.
Overall, the removal of age restrictions for neffy marks a significant advancement in anaphylaxis management, combining regulatory progress, clinical innovation, and patient-centric design. By enabling broader access to a needle-free, easy-to-administer epinephrine option, this development addresses longstanding challenges in emergency allergy care and reinforces the shift toward accessible, efficient, and life-saving healthcare solutions.
Source: ARS Pharmaceuticals press release
